Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

IN BRIEF: RTW Biotech lifts NAV on Biogen's USD85 million Alcyone deal

23rd Sep 2025 11:01

RTW Biotech Opportunities Ltd - Guernsey, Channel Islands-based investor in high-growth life science sectors - Notes Biogen Inc's agreement announced last Thursday to acquire portfolio company Alcyone Therapeutics Inc for USD85 million upfront plus milestone payments. Says the deal represents a 242% uplift on RTW's USD2.1 million carrying value of Alcyone, adding USD5.0 million, or around 0.7%, to its August 31 NAV, where Alcyone represented approximately a 0.3% position. Alcyone is developing ThecaFlex DRx, an implantable device for intrathecal delivery of neurological therapies, which Biogen plans to deploy with its marketed drug Spinraza, with a launch targeted in 2028. The transaction its RTW's second portfolio takeout this year, following Merck & Co Inc's purchase of Verona Pharma PLC, and says it highlights embedded value in its private holdings.

Current stock price: USD1.49, up 0.3% on Tuesday morning in London

12-month change: down 2.3%

By Eva Castanedo, Alliance News reporter

Comments and questions to [email protected]

Copyright 2025 Alliance News Ltd. All Rights Reserved.


Related Shares:

Rtw Biotech
FTSE 100 Latest
Value9,427.73
Change-18.70